Portada Simposios - Supplements - Haematologica

XLII Reunión Nacional de la AEHH y XVI Congreso de la SETH. Simposios
133
using AAV to deliver FIX in haemophiliacs are encouraging,
allowing us to face the future with optimism.
References
1. Ljung RCR. Prophylactic infusion requires in the management of hemophilia.
Thromb Haemost 1999; 82: 525-530.
2. Gallo-Penn AM, Shirley PS, Andrews JL et al. In vivo evaluation of an
adenoviral vector encoding canine factor VIII: high-level, sustained expression
in hemophiliac mice. Hum Gene Ther 1999; 10: 1791-1802.
3. Wang L, Takabe K, Bidlingmaier S et al. Sustained correction of bleeding
disorder in hemophilia B mice by gene therapy. Proc Natl Acad
Sci U S A 1999; 96: 3906-3910.
4. Kay MA, Rothenberg S, Landen CN et al. In vivo gene therapy for hemophilia
B: Sustained partial correction in factor IX deficient dogs.
Science 1993; 262: 117-119.
5. Chuah MK, Collen D, Vandendriessche T. Gene therapy for hemophilia:
hopes and hurdles. Crit Rev Oncol Hematol 1998; 28: 153-171.
6. Vandendriessche T, Vanslembrouck V, Goovaerts I et al. Long-term expression
of human coagulation factor VIII and correction of hemophilia
A after in vivo retroviral gene transfer in factor VIII-deficient mice.
Proc Natl Acad Sci U S A 1999; 96: 10379-10384.
7. Balagué C, Zhou J, Dai Y et al. Sustained high-level expression of
full-length human factor VIII and restoration of clotting activity in hemophilic
mice using a minimal adenovirus vector. Blood 2000; 95:
820-828.
8. Marshall E. Gene therapy death prompts review of adenovirus vector.
Science 1999; 286: 2244-2245.
9. Snyder RO, Miao CH, Patijn GA et al. Persistent and therapeutic concentrations
of human factor IX in mice after hepatic gene transfer of
recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
10. Herzog RW, Hagstrom JN, Kung SH et al. Stable gene transfer and expression
of human blood coagulation factor IX after intramuscular injection
of recombinant adeno-associated virus. Proc Natl Acad Sci U S
A 1997; 94: 5804-5809.
11. Snyder RO, Miao C, Meuse L et al. Correction of hemophilia B in canine
and murine models using recombinant adeno-associated viral vectors.
Nat Med 1999; 5: 64-70.
12. Herzog RW, Yang EY, Couto LB et al. Long-term correction of canine
hemophilia B by gene transfer of blood coagulation factor IX mediated
by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
13. Kay MA, Manno CS, Ragni MV et al. Evidence for gene transfer and expression
of factor IX in haemophilia B patients treated with an AAV vector.
Nat Genet 2000; 24: 257-261.
14. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human
factor VIII in mice using a parvovirus-based vector. Blood 2000; 95:
1594-1599.
15. Burton M, Nakai H, Colosi P et al. Coexpression of factor VIII heavy
and light chain adeno-associated viral vectors produces biologically active
protein. Proc Natl Acad Sci. USA 1999; 96: 12725-12730.
16. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis
of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med
1998; 4: 285-290.